Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

1.

STI571: targeting BCR-ABL as therapy for CML.

Mauro MJ, Druker BJ.

Oncologist. 2001;6(3):233-8. Review.

PMID:
11423669
[PubMed - indexed for MEDLINE]
Free Article
2.

[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].

Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.

Ai Zheng. 2004 Apr;23(4):421-5. Chinese.

PMID:
15087031
[PubMed - indexed for MEDLINE]
3.

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

Wolff NC, Ilaria RL Jr.

Blood. 2001 Nov 1;98(9):2808-16.

PMID:
11675355
[PubMed - indexed for MEDLINE]
Free Article
4.

Chronic myelogenous leukemia in chronic phase.

Kurzrock R, Kantarjian H, Talpaz M.

Curr Treat Options Oncol. 2001 Jun;2(3):245-52. Review.

PMID:
12057124
[PubMed - indexed for MEDLINE]
5.

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL.

N Engl J Med. 2001 Apr 5;344(14):1031-7.

PMID:
11287972
[PubMed - indexed for MEDLINE]
Free Article
6.

Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.

Hernández-Boluda JC, Cervantes F.

Drugs Today (Barc). 2002 Sep;38(9):601-13. Review.

PMID:
12582448
[PubMed - indexed for MEDLINE]
7.

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M.

Clin Cancer Res. 2002 Jul;8(7):2167-76.

PMID:
12114417
[PubMed - indexed for MEDLINE]
Free Article
8.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
[PubMed - indexed for MEDLINE]
9.

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.

Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.

Cancer. 2002 May 15;94(10):2653-62.

PMID:
12173333
[PubMed - indexed for MEDLINE]
10.

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.

Blood. 2002 May 15;99(10):3547-53.

PMID:
11986206
[PubMed - indexed for MEDLINE]
Free Article
11.

Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.

Stentoft J, Pallisgaard N, Kjeldsen E, Holm MS, Nielsen JL, Hokland P.

Eur J Haematol. 2001 Nov-Dec;67(5-6):302-8.

PMID:
11872078
[PubMed - indexed for MEDLINE]
12.

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T, Fenaux P, Preudhomme C.

Blood. 2002 Aug 1;100(3):1014-8.

PMID:
12130516
[PubMed - indexed for MEDLINE]
Free Article
13.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ.

Blood. 2002 May 15;99(10):3530-9.

PMID:
11986204
[PubMed - indexed for MEDLINE]
Free Article
14.

[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].

Molnár L, Losonczy H.

Orv Hetil. 2002 Oct 20;143(42):2379-84. Review. Hungarian.

PMID:
12440260
[PubMed - indexed for MEDLINE]
15.

[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].

Buchdunger E.

Med Klin (Munich). 2002 Jan 15;97 Suppl 1:2-6. German.

PMID:
11831067
[PubMed - indexed for MEDLINE]
16.

Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.

Nakajima M, Toga W.

Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. Review.

PMID:
14639002
[PubMed - indexed for MEDLINE]
17.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
[PubMed - indexed for MEDLINE]
18.

Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.

Kantarjian HM, Talpaz M.

Semin Oncol. 2001 Oct;28(5 Suppl 17):9-18. Review.

PMID:
11740802
[PubMed - indexed for MEDLINE]
19.

Imatinib: the first 3 years.

Capdeville R, Silberman S, Dimitrijevic S.

Eur J Cancer. 2002 Sep;38 Suppl 5:S77-82. Review.

PMID:
12528777
[PubMed - indexed for MEDLINE]
20.

[Imatinib therapy for patients with chronic myelogenous leukemia].

Usui N.

Gan To Kagaku Ryoho. 2005 Mar;32(3):297-303. Review. Japanese.

PMID:
15791812
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk